Acromegaly Treatment Market

Market Overview

According to Kings Research, the global acromegaly treatment market was estimated at USD 1,787.6 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 7.04% to reach USD 3,080.9 million by 2033. As awareness and recognition of acromegaly symptoms improve, healthcare providers are diagnosing more cases, driving demand for effective therapies.

The acromegaly treatment market includes several key companies such as Sun Pharmaceutical Industries Ltd., Chiesi Group, Peptron, Wockhardt, Pfizer Inc., ADVANZ PHARMA, Amryt Pharma plc (Chiesi Farmaceutici), Cipla, Ipsen Pharma, Viatris Inc., Zydus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Recordati Rare Diseases, Crinetics Pharmaceuticals, Inc., and Xeris Pharmaceuticals, Inc.

The market is evolving as awareness increases and diagnosis improves, particularly in developing regions where access to medical care is expanding. This growing patient population is creating significant opportunities for pharmaceutical companies and accelerating the adoption of specialized, innovative therapies.

Rising awareness and improved healthcare access are expected to contribute significantly to market growth during the forecast period. For example, in March 2024, Chiesi Global Rare Diseases launched the "Rethink Acromegaly" campaign to raise awareness and provide resources for patients, caregivers, and healthcare providers. The initiative aims to support earlier diagnosis and better disease management, which will expand the treated patient population over time.

Key Market Highlights

• The global market for acromegaly treatment was valued at USD 1,787.6 million in 2025.
• The market size is anticipated to grow at a CAGR of 7.04% during 2026-2033 and is projected to reach USD 3,080.9 million by 2033.
• North America held the largest share of 37.25% in the market in 2025, and the region was valued at USD 665.9 million.
• The segment of somatostatin analogues (SSAs) accounted for a 33.51% market share in 2025, contributing to the revenue generation of USD 599.0 million.
• The hospital pharmacies segment is projected to generate USD 1,150.5 million of the total revenue by 2033, registering a CAGR of 37.34%.
• Asia-Pacific is anticipated to grow at the fastest CAGR of 7.89% during the forecast period (2026-2033).

How is increasing clinical awareness and improved diagnostic capabilities driving market growth?

Acromegaly, though rare, is being diagnosed more frequently due to increased clinical awareness and improved diagnostic methods. The condition occurs in 3 to 14 people per 100,000 worldwide, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Endocrine guidelines from both Mayo Clinic and the Endocrine Society support this baseline clinical insight.

Growing knowledge among healthcare professionals and the public is supporting earlier detection of the disease, which in turn is driving demand for specialized, targeted treatments. Market growth is also being supported by continuous advancements in diagnostic techniques, such as high-resolution pituitary MRI imaging and standardized insulin-like growth factor 1 (IGF-1) blood assays, which improve the accuracy and timeliness of clinical diagnosis.

In September 2025, the U.S. Food and Drug Administration approved PALSONIFY (paltusotine), the first once-daily oral somatostatin receptor type 2 agonist for adult acromegaly patients, offering a milestone alternative to traditional injectable therapies.

How do challenges associated with long-term treatment management and frequent parenteral injections restrain the expansion of the global acromegaly treatment market?

Managing long-term acromegaly therapy is complex, requiring continuous biochemical monitoring, frequent parenteral injections, and regular dose adjustments. This is one of the major challenges facing the acromegaly treatment market, placing a significant burden on both patient compliance and healthcare system workflows.

Innovations such as once-daily oral therapies offer a promising solution by removing the need for frequent depot injections, improving treatment adherence, and reducing the logistical burden of chronic care administration.

How are advancements in oral formulations and novel drug delivery systems positively influencing the global acromegaly treatment market?

The acromegaly treatment market is witnessing a major shift toward more innovative, less invasive therapies, reflecting demand for treatment regimens that reduce the burden of living with a chronic condition. Patients increasingly prefer convenient routes of administration, such as oral formulations, over monthly deep intramuscular injections and frequent clinic visits.

This shift toward patient-centric innovation aims to improve long-term adherence and overall quality of life. In July 2026, the U.S. FDA accepted Camurus' resubmitted New Drug Application (NDA) for CAM2029 (octreotide subcutaneous depot / Oczyesa) for the treatment of acromegaly, with a PDUFA target action date of December 18, 2026. CAM2029 is a prefilled, autoinjector-based subcutaneous depot formulation that patients can use themselves, which may reduce the need for in-clinic dosing and make long-term therapy more convenient.

Snapshot of Acromegaly Treatment Market Report

Market Segmentation

• • By Drug Class [Somatostatin Analogues (SSAs), Growth Hormone Receptor Antagonists (GHRAs), Dopamine Agonists, and Others/Novel Pipeline Therapies]: The Somatostatin Analogues (SSAs) segment accounted for 33.51% of total market revenue in 2025, earning USD 599.0 million due to their established position as first-line medical therapy. Growth Hormone Receptor Antagonists (GHRAs), led by pegvisomant, represent a crucial second-line therapy segment for patients with incomplete SSA response, while dopamine agonists (such as cabergoline and bromocriptine) provide essential combination access. Novel oral pipeline candidates and nonpeptide SSTR2 agonists continue to expand the 'Others' segment.
  • By Route of Administration [Injectable (Intramuscular, Subcutaneous) and Oral]: Injectable products are still the largest source of revenue due to the extensive use of long-acting depot formulations (e.g., octreotide LAR, lanreotide depot). However, once daily oral paltusotine has been approved, and the oral route is rapidly penetrating the market.
  • Distribution Channel [Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies]: The hospital pharmacies segment held a 37.34% market share in 2025 and is expected to reach USD 1,150.5 million by 2033, owing to their significant contribution in providing specialized injectable formulations and rare disease therapies.

What is the market scenario across key regions in the global acromegaly treatment market?

Based on region, the market is classified into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.

North America accounted for a 37.25% share of the acromegaly treatment market in 2025, valued at USD 665.9 million. Advanced healthcare infrastructure, high disease awareness, and strong adoption of novel therapies drive this dominance. Regional growth is further supported by the presence of leading pharmaceutical innovators, substantial R&D investment, and strong reimbursement coverage that promotes high rates of diagnosis and treatment.

Asia-Pacific is projected to grow at a CAGR of 7.89% during the forecast period (2026–2033), the fastest of any region. Growth here is driven by expanding healthcare infrastructure, growing awareness of rare endocrine diseases, and improving diagnostic capabilities in key countries such as China, Japan, and India. Rapid medical advances, improved access to treatment, and supportive healthcare policies are further benefiting the region, alongside rising healthcare expenditure and a growing number of specialized endocrine centers.

Europe holds a notable share of the acromegaly treatment market, supported by strong reimbursement frameworks under national health systems and consistent rates of disease diagnosis across Germany, France, and the U.K. The region's advanced endocrinology infrastructure and early adoption of novel therapies, including oral somatostatin receptor agonists, continue to support steady market growth.

The Middle East & Africa region is expected to see steady growth, driven by improving access to specialized endocrine care and rising government investment in rare disease diagnosis, particularly across the GCC countries. However, limited awareness and diagnostic infrastructure in parts of Africa continue to constrain broader market penetration.

South and Central America represents an emerging market for acromegaly treatment, with growth supported by expanding private healthcare access and increasing physician awareness in Brazil and Argentina. Continued investment in endocrine diagnostic capacity is expected to gradually narrow the diagnosis gap and support demand for advanced therapies over the forecast period.

Regulatory Regimes

• In the U.S., the Food and Drug Administration (FDA) regulates acromegaly treatments through rigorous clinical trial requirements, pre-market approvals, orphan drug designations, and post-market safety monitoring.
• In the EU, acromegaly therapeutics are regulated by the European Medicines Agency (EMA), which enforces strict safety, efficacy, and quality standards through centralized marketing authorization and manufacturing oversight.

Competitive Landscape

Companies in the acromegaly treatment market focus on developing new therapies that offer greater convenience of administration and sustained biochemical efficacy. Key areas of development include oral formulations, extended-release injectable depots, and novel receptor agonists aimed at optimizing disease control and patient convenience.

Key Companies in the Acromegaly Treatment Market

• Sun Pharmaceutical Industries Ltd.
• Chiesi Group
• Peptron
• Wockhardt
• Pfizer Inc.
• ADVANZ PHARMA
• Amryt Pharma plc (Chiesi Farmaceutici)
• Cipla
• Ipsen Pharma
• Viatris Inc.
• Zydus Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Recordati Rare Diseases
• Crinetics Pharmaceuticals, Inc.
• Xeris Pharmaceuticals, Inc.

Recent Developments

• In July 2026, the US FDA accepted Camurus's resubmitted New Drug Application for CAM2029 (octreotide extended-release injection) to treat acromegaly.
• In September 2025, the U.S. FDA approved PALSONIFY (paltusotine) by Crinetics Pharmaceuticals, the historic approval of the first once-daily oral somatostatin receptor type 2 agonist for adults with acromegaly.
• In October 2024, Teva Pharmaceutical Industries launched the first generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the U.S., increasing cost-effective market access.